Request Demo

Last update 23 Jan 2025

Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

Last update 23 Jan 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Biological products

Synonyms

Immunotherapy(Ruprecht-Karls-Universität Heidelberg)

Target-

Mechanism-

Therapeutic Areas

Immune System Diseases

Active Indication

Graft Rejection

Inactive Indication-

Originator Organization

Ruprecht-Karls-Universität Heidelberg

Active Organization

Ruprecht-Karls-Universität Heidelberg

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Clinical Trials associated with Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

ChiCTR2400079700

/ SuspendedPhase 4IIT

KEY-VALUE: SURVEY ON THE TREATMENT PATTERN OF 1L IMMUNOTHERAPY IN CHINESE ADVANCED NSCLC PATIENTS

Start Date29 Feb 2024

Sponsor / Collaborator-

100 Clinical Results associated with Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

100 Translational Medicine associated with Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

100 Patents (Medical) associated with Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

Literatures (Medical) associated with Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

01 Jan 2025·International Immunopharmacology

Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review

Review

Author: Saburi, Ehsan ; Salimi Asl, Ali ; Seddighi, Narjes ; Arabi, Kimia ; Davari, Mohsen ; Ghorbani, Atousa

Skin cancer is the most common new cancer among Caucasians. This cancer has different types, of which non-melanoma skin cancer is the most common type. Various factors affect this disease, one of which is viral infections, including HPV. This virus plays an important role in skin cancer, especially cSCCs. There are various options for the treatment of skin cancer, and today special attention has been paid to treatments based on therapeutic goals, immunotherapy and combination therapy. In this study, we have investigated treatments based on immunotherapy and virotherapy and the effect of HPV virus on the effectiveness of these treatments in skin cancer. Treatments based on virotherapy are performed for a long time in combination with other common treatments such as radiotherapy and chemotherapy in order to have a greater effect and lower its side effects, which include: shortness of breath, tachycardia, lowering blood pressure in the patient. Also, the most important axis of immunotherapy is to focus on PD1-PDL1, despite abundant evidence on the importance of immunotherapy, many studies investigate the use of immunotherapy inhibitors in the adjuvant and neoadjuvant setting in various cancers. Also, previous findings show conflicting evidence of the effect of HPV status on the response to immunotherapy.

01 May 1999·The LancetQ1 · MEDICINE

Immunotherap y for colon cancer

Q1 · MEDICINE

Letter

Author: H. M. Pinedo ; H. Van Tinteren ; G. Parmiani ; A. M. E. Claessen ; O. Delastre ; K. V. Lukacs ; E. Blot ; A. J. A. Bremers ; J. B. Vermorken ; M. G. Hanna ; H. Levesque ; M. G. Davies

01 May 1999·The LancetQ1 · MEDICINE

Immunotherap y for colon cancer

Q1 · MEDICINE

Letter

Author: Andreas Ja Bremers ; Giorgio Parmiani

100 Deals associated with Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Graft Rejection	Phase 1	-	Ruprecht-Karls-Universität Heidelberg	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2023	Phase 3	Esophageal Carcinoma \| Advanced gastric carcinoma Adjuvant \| Maintenance	-	Chemo-immunotherapy	uwzhihyffv(jtpcpxvouv) = mqlpfiocmg gltgeriqpc (iphcxjidnw ) View more	Positive	31 May 2023
				Immunotherapy-only	uzqttsfoho(noiahykcss) = xyttfvttwt nbixfccgbc (toohenjzgx )
ASCO2023	Not Applicable	-	-	Thymosin α1+consolidative immunotherapy	(illhztpsnj) = oiiwasnpja ozdjxmlmmw (nhmfksummk ) View more	Positive	31 May 2023
				Thymosin α1+CCRT	(illhztpsnj) = agowdoscto ozdjxmlmmw (nhmfksummk ) View more
ASCO2022	Not Applicable	Non-Small Cell Lung Cancer	68	Capmatinib	aitgfscvac(oeaybljqec) = slkawoqjjq ssbbnuvaqh (gwmkefglak ) View more	Positive	02 Jun 2022
				Immunotherapy-containing regimens	aitgfscvac(oeaybljqec) = jnyaqoonym ssbbnuvaqh (gwmkefglak ) View more
ESMO2018	Not Applicable	Triple Negative Breast Cancer First line	-	Newly approved therapies (e.g. immunotherapy)	(ypwcxgjnno) = fidmnnflgm uvcmxjcqpr (azoazggttj )	-	22 Oct 2018
				Docetaxel	(ypwcxgjnno) = kmztojeeaa uvcmxjcqpr (azoazggttj )
ASCO2018	Not Applicable	Metastatic melanoma	80	Combination ipilimumab and anti-PD1 immunotherapy	hmfbaxualt(gxluzfvfel) = Hyperacute toxicities from combination immunotherapy are varied. Many pts require treatment beyond oral steroids and for a prolonged duration, and pts are at risk of further severe tox. mvuxbihzbe (gmesaofgwn )	-	01 Jun 2018
CRD42018083991 (ASCO2018)	Not Applicable	Hepatocellular Carcinoma Adjuvant	-	Non-immunotherapy	(qkrjrcitpb): HR = 0.63 (95% CI, 0.51 - 0.79) View more	Positive	01 Jun 2018
				Immunotherapy
ASCO2016	Not Applicable	Metastatic melanoma	140	Targeted therapy alone (BRAF mutant)	(ackcvikihr) = dycgzaccth khqfhdtnig (nlswgstkhp )	Positive	20 May 2016
				Targeted therapy combined with chemotherapy and/or immunotherapy (BRAF mutant)	(ackcvikihr) = ivttjtafgz khqfhdtnig (nlswgstkhp ) View more
ASCO2004	Not Applicable	Relapsing acute myeloid leukemia \| Acute lymphoblastic leukemia recurrent	97	GM-CSF + IFN	(fojxwjffac) = kmmjudfylt cvjpjavfwx (hqemeittel )	-	15 Jul 2004
				No cytokine immunotherapy	(fojxwjffac) = wyaumwklhp cvjpjavfwx (hqemeittel )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation